Following her presentation at the ESMO 2019, Dr Noemi Reguart (University of Barcelona) discusses where epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) fit into the treatment of squamous non-small cell lung cancer (NSCLC).
1. What are the limitations of the current standard of care for squamous non-small cell lung cancer (NSCLC)? (0:04)
2. How prevalent is the epidermal growth factor receptor (EGFR) mutation in squamous NSCLC and in which patient groups is it most commonly found? (5:08)
3. What evidence supports the use of EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutated squamous NSCLC? (7:36)
4. How can acquired resistance to EGFR TKIs be managed in patients with squamous NSCLC? (10:01)
5. What are the key take home messages of your presentation? (11:09)
Filmed at the European Society for Medical Oncology (ESMO) Congress 2019, Barcelona, Spain.
Speaker disclosures: Noemi Reguart has acted as an advisor/speaker for MSD, BMS, Roche, Boehringer Ingelheim, Guardant Health, Pfizer, Abbvie, Ipsen, Novartis, AstraZeneca, Lilly and Takeda.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Lung Cancer
Ahmet Sezer, ESMO 2020 – Cemiplimab in Non-small Cell Lung Cancer and the EMPOWER-Lung 1 Trial
It was a pleasure to meet Dr Ahmet Sezer to discuss the clinical development of cemiplimab as a potential treatment for non-small cell lung cancer and key safety and efficacy findings from the EMPOWER- Lung 1 study. The late-breaking abstract, ‘EMPOWER-Lung 1: Phase 3 first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small […]
Raffaele Califano, ESMO 2019 – FLAURA study in NSCLC
Our Editorial Board member, Raffaele Califano (The Christie NHS Foundation Trust) joined us at ESMO 2019 to highlight results from the FLAURA study in NSCLC (NCT02296125). Questions 1. Please describe the FLAURA trail and its reported results? (0:04) 2. Clinically, what impact do you think osimertinib will have over existing standard of care for patients […]
Niels Reinmuth, ESMO 2019 – Phase III MYSTIC trial in NSCLC
We are joined by Niels Reinmuth (Asklepios Kliniken Munich-Gauting) at ESMO 2019 to discuss his presentation on PD-L1 expression in primary tumours versus metastatic samples in the phase III MYSTIC study in first-line metastatic NSCLC. Questions 1. Could you tell us a little about the MYSTIC study and its major findings? (00:07) 2. What was […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!